Published in Blood on September 16, 2008
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27
The molecular biology of mixed lineage leukemia. Haematologica (2009) 2.58
Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell (2010) 2.44
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol (2012) 1.15
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood (2013) 1.08
ECSASB2 mediates MLL degradation during hematopoietic differentiation. Blood (2011) 0.99
The PHD3 domain of MLL acts as a CYP33-regulated switch between MLL-mediated activation and repression . Biochemistry (2010) 0.94
Molecular mechanism of MLL PHD3 and RNA recognition by the Cyp33 RRM domain. J Mol Biol (2010) 0.94
Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways. J Cell Sci (2011) 0.92
Diverse functions of PHD fingers of the MLL/KMT2 subfamily. Biochim Biophys Acta (2013) 0.91
A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity. J Biol Chem (2012) 0.89
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia (2015) 0.88
Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood (2015) 0.88
Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner. Exp Hematol (2014) 0.85
Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis. Cancers (Basel) (2012) 0.83
Epigenetic dysregulation in cancer. Am J Pathol (2009) 0.82
The role of chromatin modifiers in normal and malignant hematopoiesis. Blood (2013) 0.80
Zebrafish mll gene is essential for hematopoiesis. J Biol Chem (2011) 0.80
Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal. Blood (2014) 0.79
The molecular mechanics of mixed lineage leukemia. Oncogene (2016) 0.76
Systematic Classification of Mixed-Lineage Leukemia Fusion Partners Predicts Additional Cancer Pathways. Ann Lab Med (2016) 0.76
Reemergence of translocation t(11;19)(q23;p13.1) in the absence of clinically overt leukemia. Int J Hematol (2017) 0.75
Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther (2000) 12.54
A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature (2006) 10.73
ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature (2006) 9.30
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell (2002) 6.72
Altered Hox expression and segmental identity in Mll-mutant mice. Nature (1995) 6.60
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol (2004) 6.55
Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD. Genes Dev (2001) 4.25
Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J (1997) 4.03
Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev (2003) 4.00
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol (2004) 3.62
E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell (2007) 3.59
MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med (2004) 2.97
MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci U S A (2005) 2.87
11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci U S A (1994) 2.67
The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol (1998) 2.48
Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality. Oncogene (2001) 2.42
Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev (2006) 2.20
Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair (Amst) (2006) 2.01
Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol (2004) 1.94
MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci U S A (2003) 1.83
Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res (1994) 1.54
Protein interactions of the MLL PHD fingers modulate MLL target gene regulation in human cells. Mol Cell Biol (2001) 1.52
A specific deletion in the breakpoint cluster region of the ALL-1 gene is associated with acute lymphoblastic T-cell leukemias. Cancer Res (1996) 1.01
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell (2005) 6.12
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell (2004) 6.08
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol (2004) 3.62
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A (2005) 3.37
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol (2012) 3.15
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci U S A (2005) 2.87
The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell (2010) 2.50
Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res (2005) 2.45
Two methods of whole-genome amplification enable accurate genotyping across a 2320-SNP linkage panel. Genome Res (2004) 2.22
CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell (2011) 2.01
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood (2009) 1.90
Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res (2007) 1.82
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J (2005) 1.79
Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell (2003) 1.79
The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci U S A (2006) 1.67
The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene (2005) 1.64
Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood (2011) 1.63
APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol (2002) 1.52
Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient mice. J Virol (2005) 1.46
The advent of targeted therapeutics and implications for pathologists. Am J Clin Pathol (2002) 1.38
MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp Hematol (2010) 1.35
MLL associates with telomeres and regulates telomeric repeat-containing RNA transcription. Mol Cell Biol (2009) 1.33
Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. Int J Hematol (2007) 1.26
HOX proteins and leukemia. Int J Clin Exp Pathol (2008) 1.14
Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins. Methods Mol Biol (2009) 1.13
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood (2004) 1.09
Hedgehog signaling controls homeostasis of adult intestinal smooth muscle. Dev Biol (2011) 1.01
Dynamic patterning at the pylorus: formation of an epithelial intestine-stomach boundary in late fetal life. Dev Dyn (2009) 1.00
MLL core components give the green light to histone methylation. ACS Chem Biol (2006) 0.99
ECSASB2 mediates MLL degradation during hematopoietic differentiation. Blood (2011) 0.99
Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol (2009) 0.99
Prochondrogenic signals induce a competence for Runx2 to activate hypertrophic chondrocyte gene expression. Dev Dyn (2007) 0.97
Acute myeloid leukemia diagnosis in the 21st century. Arch Pathol Lab Med (2010) 0.90
PAFc, a key player in MLL-rearranged leukemogenesis. Oncotarget (2010) 0.89
A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity. J Biol Chem (2012) 0.89
Opioids induce renal abnormalities in tumor-bearing mice. Nephron Exp Nephrol (2007) 0.88
MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells. Cell Rep (2013) 0.86
Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins. J Biol Chem (2013) 0.83
Epigenetic dysregulation in cancer. Am J Pathol (2009) 0.82
The role of menin in hematopoiesis. Adv Exp Med Biol (2009) 0.82
Multimodality imaging of splenic lesions and the role of non-vascular, image-guided intervention. Abdom Imaging (2014) 0.81
The Cancer Genome Anatomy Project: power tools for cancer biologists. Cancer Invest (2003) 0.80
MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction. Blood (2013) 0.79
Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias? Leuk Res (2010) 0.77
MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment? Cancer Cell (2008) 0.76
Deregulation of the HOXA9/MEIS1 axis in acute leukemia. Curr Opin Hematol (2016) 0.76
MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics. Arch Pathol Lab Med (2015) 0.75
Structural basis of multimer-mediated mayhem. Cancer Cell (2006) 0.75
Cervical Mesonephric Adenocarcinoma With Novel FGFR2 Mutation. Int J Gynecol Pathol (2020) 0.75
Comprehensive Immunophenotypic Characterization of Adult and Fetal Testes, the Excretory Duct System, and Testicular and Epididymal Appendages. Appl Immunohistochem Mol Morphol (2016) 0.75
Twenty-first century pathology sign-out. Clin Lab Med (2012) 0.75